Current Status of Biomedical Products for Gene and Cell Therapy of Recessive Dystrophic Epidermolysis Bullosa

Area of Science:

• Regenerative Medicine
• Genetic Therapies
• Dermatology

Background:

• Recessive dystrophic epidermolysis bullosa (RDEB) is a severe genetic disorder caused by COL7A1 gene defects, leading to collagen type VII alpha 1 (C7) deficiency.
• Current treatment options for RDEB are limited, highlighting the need for innovative therapeutic strategies.

Purpose of the Study:

• To review current and innovative strategies in gene and cell therapy for RDEB.
• To discuss the research and development stages of various RDEB treatment products.

Main Methods:

• Allogenic mesenchymal stem/stromal cells administered intradermally and intravenously.
• Genetically modified autologous dermal fibroblasts.
• Gene replacement using viral vectors and gene editing with programmable nucleases.
• Ex vivo epidermal transplants (ETs) using autologous keratinocytes (Ks).

Main Results:

• Allogenic mesenchymal stem/stromal cells show significant promise for RDEB cell therapy.
• Gene therapy approaches, including gene replacement and editing, are advancing.
• Gene-corrected ex vivo epidermal transplants have successfully completed phase III clinical trials.
• Development of two-layer skin cell transplants and locally applied gene products.

Conclusions:

• Significant progress has been made in developing effective biomedical products for RDEB treatment.
• Gene and cell therapies represent a promising frontier for managing this severe hereditary skin disease.